SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines (LUNR) is trending amidst investor debate over a recent $175 million strategic investment that triggered share dilution, leading many to see a "buy the dip" opportunity while others anticipate further declines. Community conversation is heavily focused on the impending NASA Lunar Terrain Vehicle (LTV) contract award and upcoming earnings, which are shaping sentiment regarding the company's long-term position in the evolving space economy.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is trending after its Q4 results and the unveiling of advanced GaN and SiC power platforms designed for next-gen AI data centers. The community is actively debating the immense potential of its technology and its positioning within NVIDIA's AI ecosystem against concerns over declining revenue and the absence of definitive, revenue-generating contracts, as investors look for future business clarity.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle (CRCL) is trending following a significant Q4 earnings beat and a surge in USDC adoption, which is fueling investor speculation about a potential short squeeze. Meanwhile, the community is actively debating the company's future, weighing bullish long-term potential as a digital asset platform against bearish concerns around dilution, regulatory uncertainty (like the Clarity Act), and sensitivity to interest rates.

Oddity Tech Ltd. engages in the online retail sale of cosmetics and beauty products. Its products include lipsticks, makeup brushes, mascara, eyelash curlers, and makeup brush cleansers. The company was founded by Oran Holtzman and Shiran Holtzman-Erel on March 23, 2013 and is headquartered in Tel Aviv, Israel.

ODDITY Tech Ltd. - Ordinary Shares - Class A

A controversial short report alleging ODDITY engaged in business misrepresentation and dishonest marketing has sparked fierce debate, with many investors buying the dip on strong fundamentals, a newly announced share buyback program, and a perceived overreaction, while others foresee further declines amid claims of fraud and overvaluation.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum ($LITE) is surging after reporting strong earnings and an optimistic outlook, driven by its pivotal role in providing optical components essential for the expanding AI data center infrastructure. The stock's rapid ascent has the community sharply divided between those celebrating significant gains from this AI-driven momentum and others cautioning about extreme overvaluation.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA Group is surging after reporting strong Q4 revenue and same-store sales that exceeded expectations, coupled with an optimistic outlook for new locations and 2026 growth. This performance is fueling intense community discussion, with bulls touting its long-term potential as a category leader, while skeptics continue to question its high valuation metrics.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global (ZETA) is trending after delivering its 18th consecutive earnings beat and raise, reporting strong revenue growth and achieving positive GAAP net income. The community is actively debating its AI-powered platform and raised guidance, contrasting these strong fundamentals against broader software sector sell-offs and perceived price manipulation.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending due to a mixed earnings report showing revenue growth alongside widening losses and significant cash burn, fueling community debate over its future amid recent workforce reductions, ongoing dilution concerns from a large share resale, and a prolonged search for a permanent CEO. Investors are closely watching for clarity on its path to profitability, particularly concerning upcoming models and plans to be presented at its Investor Day.

Workday, Inc. engages in the provision of development of enterprise cloud applications for finance and human resources. It delivers financial management, human capital management and analytics applications designed for companies, educational institutions, and government agencies. The company was founded by David A. Duffield and Aneel Bhusri in 2005 and is headquartered in Pleasanton, CA.

Workday Inc - Ordinary Shares - Class A

Workday Inc

Workday is experiencing a sharp sell-off despite beating Q4 earnings estimates, as investors grapple with the company's fiscal 2027 outlook and intensified debate over AI's potential disruption to the broader enterprise software sector.

MercadoLibre, Inc. engages in the development of an online commerce platform with a focus on e-commerce and related services. It operates through the following geographical segments: Brazil, Argentina, Mexico, and Other Countries. The Other Countries segment refers to Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Panama, Peru, Bolivia, Honduras, Nicaragua, El Salvador, Guatemala, Paraguay, Uruguay, and the United States of America. Its products provide a mechanism for buying, selling, and paying as well as collecting, generating leads, and comparing lists through e-commerce transactions. The company was founded by Marcos Eduardo Galperin on October 15, 1999 and is headquartered in Montevideo, Uruguay.

MercadoLibre Inc

MercadoLibre is trending following mixed Q4 earnings, where robust revenue growth from its Latin American e-commerce and fintech operations was tempered by lower-than-expected profits due to significant investments in expansion. This has ignited community debate regarding the strategic value of sacrificing short-term margins for long-term market share, driving considerable volatility and dip-buying activity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The open-label trial enrolled 90 patients and compared Ratutrelvir with Paxlovid, an oral antiviral medication from Pfizer.</li><li>Early data analysis supports Ratutrelvir’s favorable tolerability profile, faster symptom resolution, and lack of viral rebound events, the company said.</li><li>Traws is advancing Tivoxavir Marboxil as a potential once-monthly oral preventive treatment for seasonal flu.</li></ul>Shares of Traws Pharma, Inc. (TRAW) gained about 5% in premarket trading but slipped after the opening bell following the company’s announcement that it has completed enrollment in its Phase 2 trial of Ratutrelvir, an investigational oral antiviral for mild-to-moderate COVID-19.The open-label trial enrolled 90 patients and compared Ratutrelvir with Paxlovid, an oral antiviral medication from Pfizer, used to treat mild-to-moderate COVID-19. Traws said that patients unable to take Paxlovid are often at greater risk of severe disease, and that Ratutrelvir may help address this unmet need as an alternative treatment option.Patients receiving Ratutrelvir were treated with a once-daily oral dose for 10 days, while those in the separate treatment arm received standard Paxlovid dosing for five days. According to the company, early data analysis supports Ratutrelvir’s favorable tolerability profile, faster symptom resolution, and lack of viral rebound events.“The combination of early and sustained symptom improvement, extended dosing duration, absence of viral rebound observed to date, and favorable tolerability supports the strategic hypothesis that Ratutrelvir may have utility in reducing post-acute sequelae of SARS-CoV-2 infection (Long COVID),” said Robert R. Redfield, Chief Medical Officer of Traws Pharma.<h2 class="st-heading-2">Influenza Treatment Update</h2>In addition to the COVID-19 program, Traws provided an update on Tivoxavir Marboxil, an investigational antiviral for influenza. The company is advancing the drug as a potential once-monthly oral preventive treatment for seasonal flu, expanding its pipeline of therapies targeting respiratory viral diseases.Meanwhile,&nbsp;retail sentiment for TRAW remained in the ‘bullish’ territory over the past 24 hours, amid ‘high’ message volumes.<img src="https://news.stocktwits-cdn.com/TRAW_jpg_41217ff328.webp" alt="TRAW.jpg">The stock has rebounded sharply in 2026, with <a href="https://stocktwits.com/symbol/TRAW">TRAW</a> up more than 115% amid renewed buying interest.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-mnkd-stock-jump-over-7-in-pre-market-today/cmy787FR4Wz">Why Did MNKD Stock Jump Over 7% In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

06 February 2025, Baden-Württemberg, Rottweil: A candlestick chart is opened in a trading platform on a smartphone. Photo: Silas Stein/dpa

TRAW Stock Slides In Volatile Session –  What’s The Latest On Its Phase 2 Trial For COVID-19 Treatment?

The company announced the completion of enrollment in its Phase 2 trial of Ratutrelvir, an investigational oral antiviral for mild-to-moderate COVID-19.

Equity

Traws Pharma's Oral COVID Drug Shows Comparable Results To Paxlovid

Traws Pharma reports interim Phase 2 data showing ratutrelvir performed comparably to Paxlovid in mild-to-moderate COVID-19 patients.read more...

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials ChemDiv Extends CMC Services Collaboration for...

Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.

Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19. Dover...

The U.S. Centers for Disease Control and Prevention has ended its emergency response to the H5N1 bird flu outbreak, a move that removes a key policy tailwind for vaccine developers, including Moderna, Novavax, CureVac, and Traws Pharma.The CDC reportedly deactivated its response last week and will now track bird flu alongside seasonal influenza, updating human monitoring data monthly, Bloomberg&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-07-07/bird-flu-emergency-response-ends-in-us-as-infections-decline">reported</a>.&nbsp;Animal transmission data will no longer be published, the agency said. Washington and California, two of the most affected states, have also scaled back efforts.&nbsp;California ended its emergency declaration in April, while Washington is downsizing its public health response. The U.S. Department of Health and Human Services stated that the CDC’s transition reflects a return to regular program operations.&nbsp;During the response, 375 CDC staff had been assigned to the outbreak, the agency added.The CDC’s move comes amid broader federal cutbacks. Earlier this year, HHS scrapped a $766 million deal with Moderna for developing mRNA bird flu vaccines.Public health officials said a decline in surveillance would make it harder to spot the next outbreak.&nbsp; “We are letting our guard down,” said Michael Kinch, an infectious disease expert at Stony Brook University.In January, heightened bird flu fears had boosted attention on pandemic-preparedness companies.&nbsp;The U.S. reported its first human death from H5N1 in Louisiana and awarded $306 million for avian flu response, including $176 million to&nbsp;<a href="https://stocktwits.com/symbol/MRNA">Moderna</a> for its mRNA-1018 vaccine candidate.<a href="https://stocktwits.com/symbol/NVAX">Novavax</a> had been advancing pre-clinical H5N1 vaccine research, while Germany’s&nbsp;<a href="https://stocktwits.com/symbol/CVAC">CureVac</a> partnered with&nbsp;<a href="https://stocktwits.com/symbol/GSK">GlaxoSmithKline</a> on another bird flu shot.&nbsp;Traws Pharma, which is developing a one-dose antiviral therapy called tivoxavir marboxil, disclosed promising preclinical results in December 2024 and plans a Phase 2 trial this year.Bird flu has infected at least 70 people in the U.S. since the start of the outbreak, mostly agricultural workers. While most cases have been mild, one fatality was recorded in January. The virus remains a concern in migratory birds and cattle.Retail sentiment on Stocktwits was mixed across vaccine makers: ‘bullish’ for Moderna and GSK, ‘neutral’ for Novavax, and ‘bearish’ for CureVac. Meanwhile, message volume was ‘high’ for GSK, ‘normal’ for Moderna and Novavax, and ‘extremely low’ for CureVac.Year to date, Moderna shares are down 28.8%, Novavax has fallen 22.9%, while CureVac has gained 56.8%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medical syringe is displayed on a screen, and the logo of Novavax in the background. (Photo Illustration by Nikos Pekiaridis/SOPA Images/LightRocket via Getty Images)

Cooling US Bird Flu Wave Removes Tailwind For Moderna, Novavax, CureVac, Traws Pharma

The CDC reportedly deactivated its bird flu emergency response last week, folding surveillance into its regular flu tracking and ending animal infection updates.

Traws Pharma shares surged more than 200% on Monday, reaching highs seen in June after the company announced significant progress in developing its investigational one-dose influenza therapy, tivoxavir marboxil, for H5N1 bird flu treatment.&nbsp;Trading volume skyrocketed to over 2,600 times the daily average.In laboratory studies, tivoxavir marboxil demonstrated efficacy against highly pathogenic H5N1 influenza isolates.&nbsp;Traws’ Chief Science Officer David Pauza highlighted preclinical results, showing complete survival and reduced lung virus levels in mice infected with human H5N1 isolated from a dairy worker exposed to infected cattle.&nbsp;CEO Werner Cautreels added that Phase 1 clinical trial data confirmed the therapy’s safety and tolerability.&nbsp;A Phase 2 study is planned for the first half of 2025, the company said.The announcement comes amid escalating concerns over H5N1’s&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.nbcnews.com/health/health-news/bird-flu-cases-spread-warning-signs-rcna185084">spread</a>.&nbsp;The U.S. has reported 64 infections since April, with dairy herds in 16 states affected.&nbsp;Last week, California declared a state of emergency after an uptick in cases among dairy cows, and Louisiana reported the country’s first severe human infection.Retail interest&nbsp;in Traws surged on Monday, making its stock one of the top three trending symbols on Stocktwits.&nbsp;Discussions on the platform were mixed, with some predicting a breakout above $20 — a level last seen in April — and others cautioning about a potential share offering due to the company’s tight financial position.&nbsp;<stembedurl>https://stocktwits.com/miraclehunter/message/597607177</stembedurl><stembedurl>https://stocktwits.com/MarketAce/message/597606552</stembedurl>As of the last quarter, Traws had $5.4 million in cash and $11 million in liabilities, according to data on Koyfin.In addition to tivoxavir marboxil, Traws Pharma’s pipeline includes ratutrelvir for COVID-19, targeting viral proteases, and investigational cancer therapies like narazaciclib and rigosertib, which focus on cell cycle proteins.Traws Pharma began trading on&nbsp;the Nasdaq in April following the acquisition of Trawsfynydd Therapeutics by Onconova Therapeutics.&nbsp;Still, the stock remains down 24% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A view of chickens and a rooster at a farm as California declares a state of emergency to prevent a new public health crisis on Bird flu in Pescadero, California, United States on December 20, 2024. (Photo by Tayfun Coskun/Anadolu via Getty Images)

Traws Pharma Stock Hits 6-Month Highs On Bird Flu Treatment Breakthrough, Retail Interest Soars

The U.S. has reported H5N1 Bird Flu 64 infections since April, with dairy herds in 16 states affected. 

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

Traws Pharma Inc.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

Ahead of earnings, sentiment is split between blowout AI growth and concerns around macro pressure, positioning, and post-ER volatility. How do you see it playing out?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$1.22	--	--	N/A
Q3 '25	--	-$0.34	--	N/A
Q2 '25	--	-$0.11	--	N/A
Q1 '25	--	$2.09	--	N/A
Q4 '24	-$9.55	$101.35	1161.26%	BEAT

TRAW
Traws Pharma Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest TRAW News

TRAWTraws Pharma Inc.